Peter Mourani
Concepts (507)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchopulmonary Dysplasia | 23 | 2021 | 410 | 4.320 |
Why?
| | Intensive Care Units, Pediatric | 35 | 2026 | 285 | 3.350 |
Why?
| | Heart Arrest | 22 | 2025 | 407 | 3.170 |
Why?
| | Cardiopulmonary Resuscitation | 22 | 2025 | 340 | 2.970 |
Why?
| | Respiration, Artificial | 20 | 2024 | 708 | 2.550 |
Why?
| | Pneumonia, Ventilator-Associated | 4 | 2025 | 57 | 1.920 |
Why?
| | Critical Illness | 26 | 2026 | 891 | 1.910 |
Why?
| | Microbiota | 10 | 2026 | 781 | 1.860 |
Why?
| | Hypertension, Pulmonary | 13 | 2023 | 1980 | 1.750 |
Why?
| | Infant, Premature | 17 | 2021 | 611 | 1.730 |
Why?
| | Shock, Septic | 12 | 2024 | 216 | 1.650 |
Why?
| | Respiratory Tract Infections | 8 | 2026 | 397 | 1.600 |
Why?
| | Prospective Studies | 54 | 2025 | 7990 | 1.510 |
Why?
| | Sepsis | 13 | 2025 | 640 | 1.440 |
Why?
| | Child | 105 | 2026 | 22633 | 1.420 |
Why?
| | Trachea | 4 | 2026 | 261 | 1.400 |
Why?
| | Respiratory Insufficiency | 6 | 2024 | 326 | 1.370 |
Why?
| | Infant, Newborn | 47 | 2026 | 6429 | 1.310 |
Why?
| | Infant | 59 | 2026 | 10034 | 1.130 |
Why?
| | Child, Preschool | 54 | 2026 | 11787 | 1.110 |
Why?
| | Skin Pigmentation | 2 | 2025 | 48 | 1.090 |
Why?
| | Oximetry | 2 | 2025 | 126 | 1.040 |
Why?
| | Vascular Diseases | 5 | 2020 | 251 | 1.010 |
Why?
| | Humans | 151 | 2026 | 144759 | 0.890 |
Why?
| | Premature Birth | 4 | 2021 | 380 | 0.890 |
Why?
| | Lung | 10 | 2024 | 4109 | 0.860 |
Why?
| | Intubation, Intratracheal | 4 | 2024 | 320 | 0.830 |
Why?
| | Critical Care | 6 | 2021 | 695 | 0.830 |
Why?
| | Epinephrine | 5 | 2025 | 155 | 0.820 |
Why?
| | Accelerometry | 1 | 2024 | 119 | 0.810 |
Why?
| | Echocardiography | 7 | 2021 | 652 | 0.810 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2022 | 248 | 0.800 |
Why?
| | Heart Ventricles | 2 | 2021 | 760 | 0.780 |
Why?
| | Influenza, Human | 9 | 2023 | 616 | 0.770 |
Why?
| | Noninvasive Ventilation | 1 | 2024 | 62 | 0.760 |
Why?
| | Intensive Care Units | 11 | 2025 | 916 | 0.730 |
Why?
| | RNA, Ribosomal, 16S | 4 | 2021 | 558 | 0.710 |
Why?
| | Male | 78 | 2026 | 72315 | 0.700 |
Why?
| | Female | 83 | 2026 | 78271 | 0.690 |
Why?
| | Bacteria | 7 | 2026 | 889 | 0.680 |
Why?
| | Ventricular Function, Right | 2 | 2021 | 297 | 0.680 |
Why?
| | Respiratory Syncytial Virus Infections | 3 | 2019 | 136 | 0.670 |
Why?
| | Quality of Life | 13 | 2024 | 3185 | 0.670 |
Why?
| | Gestational Age | 8 | 2025 | 975 | 0.670 |
Why?
| | Adolescent | 50 | 2026 | 22428 | 0.670 |
Why?
| | Patient Discharge | 13 | 2024 | 983 | 0.640 |
Why?
| | Tobacco Smoke Pollution | 1 | 2023 | 233 | 0.640 |
Why?
| | Aftercare | 5 | 2024 | 223 | 0.570 |
Why?
| | Nutritional Support | 1 | 2017 | 39 | 0.530 |
Why?
| | Respiratory Tract Diseases | 1 | 2019 | 175 | 0.520 |
Why?
| | Echocardiography, Doppler | 3 | 2018 | 115 | 0.520 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2017 | 106 | 0.510 |
Why?
| | Patient Readmission | 3 | 2024 | 758 | 0.500 |
Why?
| | Respiratory Syncytial Viruses | 2 | 2013 | 58 | 0.480 |
Why?
| | Metagenomics | 6 | 2025 | 181 | 0.470 |
Why?
| | Coinfection | 3 | 2022 | 141 | 0.460 |
Why?
| | Risk Factors | 21 | 2024 | 10779 | 0.460 |
Why?
| | Echocardiography, Doppler, Pulsed | 1 | 2015 | 14 | 0.450 |
Why?
| | Pulmonary Artery | 4 | 2024 | 1134 | 0.450 |
Why?
| | Nitric Oxide | 6 | 2022 | 897 | 0.440 |
Why?
| | Energy Intake | 1 | 2017 | 499 | 0.430 |
Why?
| | Retrospective Studies | 30 | 2026 | 17066 | 0.420 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2014 | 24 | 0.420 |
Why?
| | Paramyxoviridae Infections | 1 | 2013 | 12 | 0.410 |
Why?
| | Metapneumovirus | 1 | 2013 | 15 | 0.410 |
Why?
| | Chlorides | 3 | 2020 | 142 | 0.410 |
Why?
| | Myocardial Contraction | 1 | 2015 | 298 | 0.400 |
Why?
| | Pneumonia, Bacterial | 2 | 2025 | 113 | 0.400 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2014 | 111 | 0.400 |
Why?
| | Proteomics | 5 | 2024 | 1195 | 0.390 |
Why?
| | Oxygen | 4 | 2024 | 995 | 0.380 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2015 | 182 | 0.380 |
Why?
| | Exercise | 1 | 2024 | 2201 | 0.370 |
Why?
| | Peripheral Vascular Diseases | 1 | 2013 | 104 | 0.370 |
Why?
| | Pulmonary Embolism | 2 | 2012 | 244 | 0.360 |
Why?
| | Lung Diseases | 2 | 2010 | 787 | 0.360 |
Why?
| | Bacterial Infections | 3 | 2023 | 246 | 0.360 |
Why?
| | Ventricular Function, Left | 1 | 2015 | 541 | 0.350 |
Why?
| | Biomarkers | 11 | 2025 | 4271 | 0.350 |
Why?
| | Denys-Drash Syndrome | 1 | 2011 | 4 | 0.350 |
Why?
| | Energy Metabolism | 1 | 2017 | 935 | 0.350 |
Why?
| | Embolectomy | 1 | 2011 | 13 | 0.350 |
Why?
| | Brain Injuries, Traumatic | 3 | 2023 | 441 | 0.340 |
Why?
| | Drug Resistance, Bacterial | 2 | 2025 | 196 | 0.340 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2020 | 392 | 0.330 |
Why?
| | Bereavement | 2 | 2021 | 62 | 0.330 |
Why?
| | Venous Thromboembolism | 2 | 2012 | 324 | 0.330 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2025 | 549 | 0.330 |
Why?
| | Influenza A virus | 3 | 2020 | 113 | 0.320 |
Why?
| | Wilms Tumor | 1 | 2011 | 85 | 0.320 |
Why?
| | Milrinone | 2 | 2021 | 26 | 0.310 |
Why?
| | Cardiopulmonary Bypass | 2 | 2025 | 221 | 0.310 |
Why?
| | Vasodilator Agents | 3 | 2021 | 331 | 0.310 |
Why?
| | Health Resources | 5 | 2024 | 129 | 0.310 |
Why?
| | Proteome | 2 | 2024 | 518 | 0.300 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1560 | 0.300 |
Why?
| | Acute Kidney Injury | 4 | 2021 | 865 | 0.300 |
Why?
| | Logistic Models | 7 | 2024 | 2117 | 0.300 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2008 | 73 | 0.280 |
Why?
| | Water-Electrolyte Imbalance | 2 | 2020 | 42 | 0.280 |
Why?
| | Coronary Care Units | 2 | 2018 | 26 | 0.280 |
Why?
| | Infant, Extremely Premature | 2 | 2020 | 67 | 0.280 |
Why?
| | Hemodynamics | 4 | 2025 | 1121 | 0.270 |
Why?
| | Sulfones | 1 | 2008 | 127 | 0.270 |
Why?
| | Multiple Organ Failure | 3 | 2023 | 124 | 0.270 |
Why?
| | Hernia, Diaphragmatic | 1 | 2008 | 67 | 0.270 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2022 | 248 | 0.270 |
Why?
| | Administration, Inhalation | 5 | 2022 | 574 | 0.260 |
Why?
| | Pregnancy | 12 | 2026 | 7190 | 0.260 |
Why?
| | Heart Diseases | 2 | 2023 | 349 | 0.260 |
Why?
| | Staphylococcus | 2 | 2017 | 74 | 0.250 |
Why?
| | Time Factors | 11 | 2025 | 7173 | 0.250 |
Why?
| | Kidney Neoplasms | 1 | 2011 | 412 | 0.250 |
Why?
| | Cohort Studies | 13 | 2022 | 5960 | 0.250 |
Why?
| | Caregivers | 4 | 2024 | 1049 | 0.250 |
Why?
| | Research Design | 4 | 2022 | 1135 | 0.250 |
Why?
| | Length of Stay | 5 | 2025 | 1337 | 0.240 |
Why?
| | Staphylococcal Infections | 2 | 2022 | 388 | 0.240 |
Why?
| | Quality Improvement | 3 | 2022 | 1289 | 0.240 |
Why?
| | Piperazines | 1 | 2008 | 381 | 0.230 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2008 | 219 | 0.230 |
Why?
| | Anti-Bacterial Agents | 5 | 2025 | 1907 | 0.230 |
Why?
| | Carrier State | 1 | 2026 | 79 | 0.230 |
Why?
| | Cloud Computing | 1 | 2025 | 6 | 0.230 |
Why?
| | Spectrophotometry | 1 | 2025 | 61 | 0.230 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2021 | 383 | 0.230 |
Why?
| | Follow-Up Studies | 8 | 2021 | 5408 | 0.230 |
Why?
| | Hospital Mortality | 8 | 2023 | 1030 | 0.220 |
Why?
| | Longitudinal Studies | 5 | 2026 | 2947 | 0.220 |
Why?
| | Bacteriological Techniques | 1 | 2025 | 68 | 0.210 |
Why?
| | Heart Bypass, Right | 1 | 2024 | 17 | 0.210 |
Why?
| | Diastole | 3 | 2019 | 143 | 0.210 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2025 | 53 | 0.210 |
Why?
| | Arteriovenous Malformations | 1 | 2024 | 29 | 0.210 |
Why?
| | Ribosomal Protein S6 | 1 | 2004 | 18 | 0.210 |
Why?
| | Hypercapnia | 1 | 2024 | 54 | 0.210 |
Why?
| | Arteriovenous Fistula | 1 | 2024 | 38 | 0.210 |
Why?
| | DEAD Box Protein 58 | 2 | 2022 | 7 | 0.210 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2004 | 35 | 0.210 |
Why?
| | Tunica Intima | 1 | 2004 | 79 | 0.200 |
Why?
| | Bradycardia | 1 | 2024 | 59 | 0.200 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2004 | 452 | 0.200 |
Why?
| | Pregnancy in Diabetics | 2 | 2024 | 121 | 0.200 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2024 | 124 | 0.200 |
Why?
| | Medical Marijuana | 1 | 2025 | 123 | 0.200 |
Why?
| | Drug Prescriptions | 1 | 2026 | 284 | 0.200 |
Why?
| | Young Adult | 12 | 2026 | 14105 | 0.200 |
Why?
| | Pulmonary Veins | 1 | 2024 | 105 | 0.200 |
Why?
| | Respiration | 1 | 2024 | 206 | 0.190 |
Why?
| | Magnetic Resonance Imaging | 4 | 2025 | 3863 | 0.190 |
Why?
| | Treatment Outcome | 12 | 2025 | 11679 | 0.190 |
Why?
| | Educational Measurement | 1 | 2026 | 326 | 0.190 |
Why?
| | Employment | 1 | 2024 | 188 | 0.190 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2004 | 167 | 0.190 |
Why?
| | Cotinine | 1 | 2023 | 79 | 0.190 |
Why?
| | Receptors, Immunologic | 2 | 2022 | 206 | 0.190 |
Why?
| | Feasibility Studies | 2 | 2024 | 1095 | 0.190 |
Why?
| | Hypotension | 1 | 2023 | 126 | 0.180 |
Why?
| | Age Factors | 6 | 2021 | 3333 | 0.180 |
Why?
| | Neuroimaging | 1 | 2025 | 289 | 0.180 |
Why?
| | Blood Proteins | 1 | 2024 | 249 | 0.180 |
Why?
| | Viruses | 1 | 2024 | 165 | 0.180 |
Why?
| | United States | 13 | 2025 | 15966 | 0.180 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2022 | 27 | 0.180 |
Why?
| | Hypoxia | 3 | 2024 | 1199 | 0.180 |
Why?
| | Meconium Aspiration Syndrome | 1 | 2022 | 10 | 0.180 |
Why?
| | Virus Diseases | 1 | 2024 | 216 | 0.180 |
Why?
| | Fontan Procedure | 1 | 2024 | 191 | 0.180 |
Why?
| | Arkansas | 3 | 2026 | 21 | 0.180 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2004 | 266 | 0.180 |
Why?
| | Protein Kinases | 1 | 2004 | 315 | 0.180 |
Why?
| | Adult | 15 | 2026 | 40449 | 0.180 |
Why?
| | Sodium | 1 | 2022 | 197 | 0.180 |
Why?
| | Central Venous Catheters | 1 | 2022 | 52 | 0.170 |
Why?
| | Smoke | 1 | 2023 | 148 | 0.170 |
Why?
| | Prone Position | 1 | 2021 | 24 | 0.170 |
Why?
| | Glasgow Coma Scale | 4 | 2023 | 213 | 0.170 |
Why?
| | Central Venous Pressure | 1 | 2021 | 16 | 0.170 |
Why?
| | Wounds and Injuries | 2 | 2021 | 956 | 0.170 |
Why?
| | Capnography | 1 | 2021 | 16 | 0.170 |
Why?
| | Indoles | 1 | 2025 | 501 | 0.170 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2022 | 81 | 0.170 |
Why?
| | ADAMTS4 Protein | 1 | 2020 | 16 | 0.170 |
Why?
| | Iloprost | 1 | 2021 | 44 | 0.170 |
Why?
| | Shock | 1 | 2022 | 108 | 0.170 |
Why?
| | Spinal Injuries | 1 | 2021 | 58 | 0.160 |
Why?
| | Common Data Elements | 1 | 2020 | 15 | 0.160 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2022 | 145 | 0.160 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2021 | 341 | 0.160 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2021 | 69 | 0.160 |
Why?
| | Vasopressins | 1 | 2021 | 60 | 0.160 |
Why?
| | Thoracic Injuries | 1 | 2021 | 72 | 0.160 |
Why?
| | Patient Positioning | 1 | 2021 | 70 | 0.160 |
Why?
| | Parents | 4 | 2021 | 1403 | 0.160 |
Why?
| | Proto-Oncogene Proteins | 1 | 2004 | 623 | 0.160 |
Why?
| | Extremities | 1 | 2021 | 140 | 0.160 |
Why?
| | Communicable Diseases | 1 | 2022 | 163 | 0.160 |
Why?
| | Socioeconomic Factors | 3 | 2020 | 1326 | 0.160 |
Why?
| | Multiple Trauma | 1 | 2021 | 116 | 0.160 |
Why?
| | Epoprostenol | 1 | 2021 | 131 | 0.160 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2021 | 96 | 0.160 |
Why?
| | Catheterization, Central Venous | 1 | 2022 | 122 | 0.160 |
Why?
| | Angiogenic Proteins | 1 | 2020 | 14 | 0.160 |
Why?
| | Abdominal Injuries | 1 | 2021 | 127 | 0.160 |
Why?
| | Radiography, Thoracic | 1 | 2021 | 171 | 0.150 |
Why?
| | Multivariate Analysis | 4 | 2018 | 1539 | 0.150 |
Why?
| | Brain Injuries | 1 | 2025 | 507 | 0.150 |
Why?
| | Morbidity | 4 | 2022 | 323 | 0.150 |
Why?
| | Medical Audit | 1 | 2020 | 77 | 0.150 |
Why?
| | Sensitivity and Specificity | 4 | 2025 | 1985 | 0.150 |
Why?
| | Mannose-Binding Lectin | 1 | 2019 | 20 | 0.150 |
Why?
| | Medical Records | 1 | 2020 | 187 | 0.150 |
Why?
| | Computational Biology | 2 | 2025 | 680 | 0.150 |
Why?
| | Cardiotonic Agents | 1 | 2019 | 95 | 0.140 |
Why?
| | Muscular Dystrophy, Duchenne | 1 | 2020 | 91 | 0.140 |
Why?
| | Nervous System Diseases | 1 | 2022 | 284 | 0.140 |
Why?
| | Medicine | 1 | 2020 | 125 | 0.140 |
Why?
| | Pulmonary Circulation | 2 | 2015 | 430 | 0.140 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 189 | 0.140 |
Why?
| | Reproducibility of Results | 4 | 2020 | 3409 | 0.140 |
Why?
| | Genetic Predisposition to Disease | 3 | 2019 | 2363 | 0.140 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 1 | 2017 | 29 | 0.140 |
Why?
| | CRISPR-Cas Systems | 1 | 2019 | 170 | 0.130 |
Why?
| | Toll-Like Receptor 4 | 1 | 2020 | 276 | 0.130 |
Why?
| | Calorimetry, Indirect | 1 | 2017 | 83 | 0.130 |
Why?
| | Diabetes, Gestational | 1 | 2022 | 321 | 0.130 |
Why?
| | Blood Pressure | 4 | 2023 | 1769 | 0.130 |
Why?
| | Transcriptome | 4 | 2026 | 1045 | 0.130 |
Why?
| | RNA, Bacterial | 2 | 2024 | 189 | 0.130 |
Why?
| | Medical Staff, Hospital | 1 | 2018 | 80 | 0.130 |
Why?
| | Academic Medical Centers | 2 | 2017 | 547 | 0.130 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2017 | 73 | 0.130 |
Why?
| | Chorioamnionitis | 1 | 2017 | 45 | 0.130 |
Why?
| | Respiratory System | 1 | 2018 | 149 | 0.130 |
Why?
| | Mutation, Missense | 1 | 2019 | 340 | 0.130 |
Why?
| | Renal Replacement Therapy | 1 | 2018 | 100 | 0.130 |
Why?
| | Inservice Training | 1 | 2018 | 117 | 0.130 |
Why?
| | Cardiac Surgical Procedures | 1 | 2023 | 609 | 0.130 |
Why?
| | Analgesics, Opioid | 1 | 2026 | 1143 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 771 | 0.130 |
Why?
| | Dysbiosis | 1 | 2018 | 187 | 0.130 |
Why?
| | Motivation | 1 | 2021 | 610 | 0.120 |
Why?
| | Chronic Disease | 3 | 2022 | 1813 | 0.120 |
Why?
| | Ultrasonography | 2 | 2025 | 770 | 0.120 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2018 | 594 | 0.120 |
Why?
| | Delirium | 1 | 2018 | 104 | 0.120 |
Why?
| | Heart Failure | 2 | 2021 | 2323 | 0.120 |
Why?
| | Drug Administration Schedule | 2 | 2024 | 779 | 0.120 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2017 | 106 | 0.120 |
Why?
| | Hospitalization | 4 | 2023 | 2433 | 0.120 |
Why?
| | Incidence | 3 | 2024 | 2879 | 0.120 |
Why?
| | Observer Variation | 1 | 2017 | 355 | 0.120 |
Why?
| | Pneumonia | 1 | 2022 | 631 | 0.120 |
Why?
| | Infant, Low Birth Weight | 2 | 2015 | 153 | 0.120 |
Why?
| | MicroRNAs | 1 | 2022 | 701 | 0.120 |
Why?
| | Prognosis | 5 | 2025 | 4282 | 0.120 |
Why?
| | Endothelium-Dependent Relaxing Factors | 1 | 2015 | 17 | 0.120 |
Why?
| | Practice Patterns, Physicians' | 1 | 2025 | 1356 | 0.110 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 279 | 0.110 |
Why?
| | Tandem Mass Spectrometry | 1 | 2018 | 576 | 0.110 |
Why?
| | Survival Rate | 4 | 2024 | 2089 | 0.110 |
Why?
| | Organ Dysfunction Scores | 3 | 2020 | 53 | 0.110 |
Why?
| | Pre-Eclampsia | 1 | 2017 | 204 | 0.110 |
Why?
| | Mothers | 2 | 2022 | 775 | 0.110 |
Why?
| | Hyperglycemia | 1 | 2019 | 375 | 0.110 |
Why?
| | Severity of Illness Index | 5 | 2020 | 2925 | 0.110 |
Why?
| | Heart Defects, Congenital | 2 | 2024 | 914 | 0.110 |
Why?
| | Indiana | 1 | 2015 | 37 | 0.110 |
Why?
| | Fibroblasts | 1 | 2020 | 1034 | 0.110 |
Why?
| | Medical Informatics | 1 | 2016 | 97 | 0.110 |
Why?
| | Needs Assessment | 1 | 2017 | 404 | 0.110 |
Why?
| | Hypokalemia | 1 | 2014 | 24 | 0.110 |
Why?
| | Delphi Technique | 3 | 2020 | 329 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2019 | 384 | 0.100 |
Why?
| | Vasoconstrictor Agents | 2 | 2025 | 144 | 0.100 |
Why?
| | Trauma Centers | 3 | 2022 | 462 | 0.100 |
Why?
| | Bronchiolitis, Viral | 1 | 2013 | 10 | 0.100 |
Why?
| | Hospitals, Pediatric | 3 | 2023 | 556 | 0.100 |
Why?
| | Birth Weight | 1 | 2017 | 522 | 0.100 |
Why?
| | Schools, Medical | 1 | 2015 | 156 | 0.100 |
Why?
| | Smoking | 2 | 2018 | 1472 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 2 | 2025 | 2730 | 0.100 |
Why?
| | Hypertension | 2 | 2019 | 1263 | 0.100 |
Why?
| | RNA-Binding Proteins | 1 | 2017 | 462 | 0.100 |
Why?
| | Aged | 5 | 2024 | 25913 | 0.100 |
Why?
| | Hyperoxia | 2 | 2024 | 99 | 0.100 |
Why?
| | Metabolomics | 1 | 2018 | 727 | 0.100 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2021 | 893 | 0.090 |
Why?
| | Signal Transduction | 2 | 2020 | 5226 | 0.090 |
Why?
| | Cerebral Arterial Diseases | 1 | 2012 | 49 | 0.090 |
Why?
| | Nasopharynx | 2 | 2023 | 73 | 0.090 |
Why?
| | Risk Assessment | 5 | 2018 | 3671 | 0.090 |
Why?
| | Colorado | 4 | 2017 | 4564 | 0.090 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2012 | 93 | 0.090 |
Why?
| | Viral Load | 2 | 2024 | 526 | 0.090 |
Why?
| | Adaptive Immunity | 2 | 2024 | 169 | 0.090 |
Why?
| | Risk | 2 | 2012 | 911 | 0.090 |
Why?
| | Physicians | 1 | 2021 | 939 | 0.090 |
Why?
| | Patient Care Team | 1 | 2018 | 689 | 0.090 |
Why?
| | Antiphospholipid Syndrome | 1 | 2012 | 33 | 0.090 |
Why?
| | Polysaccharides | 1 | 2012 | 87 | 0.090 |
Why?
| | Carbon Dioxide | 2 | 2023 | 242 | 0.090 |
Why?
| | Abbreviated Injury Scale | 2 | 2021 | 27 | 0.090 |
Why?
| | Diabetic Ketoacidosis | 1 | 2014 | 210 | 0.090 |
Why?
| | Suction | 1 | 2011 | 33 | 0.090 |
Why?
| | Bacterial Load | 1 | 2011 | 67 | 0.090 |
Why?
| | Enoxaparin | 1 | 2012 | 67 | 0.090 |
Why?
| | Precision Medicine | 1 | 2016 | 457 | 0.090 |
Why?
| | Fatal Outcome | 1 | 2012 | 307 | 0.090 |
Why?
| | Immunomodulation | 1 | 2012 | 101 | 0.090 |
Why?
| | Grief | 2 | 2021 | 47 | 0.080 |
Why?
| | Pressure | 2 | 2023 | 225 | 0.080 |
Why?
| | RNA, Ribosomal | 1 | 2011 | 168 | 0.080 |
Why?
| | Membrane Proteins | 1 | 2017 | 1166 | 0.080 |
Why?
| | Anti-Infective Agents | 1 | 2013 | 242 | 0.080 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 189 | 0.080 |
Why?
| | Metagenome | 1 | 2011 | 149 | 0.080 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2017 | 675 | 0.080 |
Why?
| | Interferons | 2 | 2022 | 188 | 0.080 |
Why?
| | Adrenal Cortex Hormones | 2 | 2024 | 478 | 0.080 |
Why?
| | Anticoagulants | 2 | 2012 | 722 | 0.080 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 291 | 0.080 |
Why?
| | Vitamin D | 1 | 2013 | 400 | 0.080 |
Why?
| | Intensive Care, Neonatal | 1 | 2010 | 42 | 0.080 |
Why?
| | Fetal Blood | 1 | 2012 | 342 | 0.080 |
Why?
| | Stakeholder Participation | 2 | 2020 | 84 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 2019 | 1387 | 0.070 |
Why?
| | Influenza Vaccines | 1 | 2014 | 529 | 0.070 |
Why?
| | Antihypertensive Agents | 1 | 2013 | 510 | 0.070 |
Why?
| | Potassium | 2 | 2022 | 152 | 0.070 |
Why?
| | Sildenafil Citrate | 1 | 2008 | 60 | 0.070 |
Why?
| | Blood Glucose | 2 | 2019 | 2327 | 0.070 |
Why?
| | Survivors | 2 | 2022 | 520 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2026 | 3604 | 0.070 |
Why?
| | Gene Expression Profiling | 3 | 2026 | 1782 | 0.070 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2008 | 67 | 0.070 |
Why?
| | Pulmonary Edema | 1 | 2008 | 106 | 0.070 |
Why?
| | Stem Cells | 1 | 2012 | 626 | 0.070 |
Why?
| | Purines | 1 | 2008 | 187 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2024 | 1217 | 0.070 |
Why?
| | Pediatrics | 1 | 2016 | 1114 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2023 | 983 | 0.070 |
Why?
| | Diseases in Twins | 1 | 2008 | 115 | 0.060 |
Why?
| | Surveys and Questionnaires | 4 | 2021 | 6048 | 0.060 |
Why?
| | Stroke Volume | 2 | 2021 | 651 | 0.060 |
Why?
| | Survival Analysis | 2 | 2022 | 1382 | 0.060 |
Why?
| | Gene Expression | 2 | 2022 | 1490 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2018 | 2919 | 0.060 |
Why?
| | Prescription Drug Monitoring Programs | 1 | 2026 | 17 | 0.060 |
Why?
| | Indoleacetic Acids | 1 | 2025 | 10 | 0.060 |
Why?
| | Neovascularization, Physiologic | 2 | 2012 | 194 | 0.060 |
Why?
| | Phenotype | 2 | 2023 | 3162 | 0.060 |
Why?
| | Cell Division | 2 | 2004 | 766 | 0.050 |
Why?
| | Angiopoietin-2 | 1 | 2024 | 15 | 0.050 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2025 | 68 | 0.050 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2025 | 124 | 0.050 |
Why?
| | Neurofilament Proteins | 1 | 2025 | 78 | 0.050 |
Why?
| | Hypocapnia | 1 | 2024 | 8 | 0.050 |
Why?
| | Clinical Competence | 2 | 2023 | 1244 | 0.050 |
Why?
| | Culture Media, Serum-Free | 1 | 2004 | 42 | 0.050 |
Why?
| | Cytokines | 1 | 2012 | 2061 | 0.050 |
Why?
| | Chromones | 1 | 2004 | 42 | 0.050 |
Why?
| | Diffuse Axonal Injury | 1 | 2023 | 8 | 0.050 |
Why?
| | Cardiac Catheterization | 1 | 2008 | 560 | 0.050 |
Why?
| | Propensity Score | 1 | 2026 | 367 | 0.050 |
Why?
| | Carotid Artery Injuries | 1 | 2004 | 39 | 0.050 |
Why?
| | Whole Genome Sequencing | 1 | 2025 | 182 | 0.050 |
Why?
| | Androstadienes | 1 | 2004 | 76 | 0.050 |
Why?
| | Drug Resistance, Microbial | 1 | 2024 | 69 | 0.050 |
Why?
| | Disaccharides | 1 | 2023 | 21 | 0.050 |
Why?
| | Adaptive Clinical Trials as Topic | 1 | 2023 | 24 | 0.050 |
Why?
| | Aorta | 2 | 2004 | 429 | 0.050 |
Why?
| | Stroke | 1 | 2012 | 1256 | 0.050 |
Why?
| | Syndecan-1 | 1 | 2023 | 42 | 0.050 |
Why?
| | Oligonucleotides, Antisense | 1 | 2004 | 116 | 0.050 |
Why?
| | Corpus Callosum | 1 | 2023 | 72 | 0.050 |
Why?
| | Glycocalyx | 1 | 2023 | 30 | 0.050 |
Why?
| | Chondroitin Sulfates | 1 | 2023 | 35 | 0.050 |
Why?
| | Probability | 1 | 2004 | 310 | 0.050 |
Why?
| | Morpholines | 1 | 2004 | 128 | 0.050 |
Why?
| | Water-Electrolyte Balance | 1 | 2023 | 36 | 0.050 |
Why?
| | Catheterization | 1 | 2004 | 183 | 0.050 |
Why?
| | Proteoglycans | 1 | 2023 | 110 | 0.050 |
Why?
| | Vascular Resistance | 1 | 2004 | 367 | 0.050 |
Why?
| | Methicillin | 1 | 2022 | 10 | 0.050 |
Why?
| | Chemotactic Factors | 1 | 2022 | 43 | 0.050 |
Why?
| | Dronabinol | 1 | 2025 | 247 | 0.050 |
Why?
| | PTEN Phosphohydrolase | 1 | 2004 | 164 | 0.050 |
Why?
| | Pregnancy Outcome | 1 | 2026 | 476 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2022 | 2145 | 0.050 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2023 | 161 | 0.050 |
Why?
| | Sirolimus | 1 | 2004 | 281 | 0.050 |
Why?
| | Respiratory Function Tests | 1 | 2004 | 547 | 0.050 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2023 | 253 | 0.050 |
Why?
| | Sodium Bicarbonate | 1 | 2022 | 47 | 0.050 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2024 | 636 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2004 | 380 | 0.040 |
Why?
| | RNA, Viral | 2 | 2017 | 688 | 0.040 |
Why?
| | White Matter | 1 | 2023 | 153 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2004 | 436 | 0.040 |
Why?
| | Haemophilus influenzae | 1 | 2022 | 67 | 0.040 |
Why?
| | Cost of Illness | 1 | 2024 | 321 | 0.040 |
Why?
| | Norepinephrine | 1 | 2022 | 196 | 0.040 |
Why?
| | Neonatologists | 1 | 2021 | 9 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2004 | 477 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 442 | 0.040 |
Why?
| | Influenza in Birds | 1 | 2020 | 5 | 0.040 |
Why?
| | Patient Acuity | 1 | 2021 | 47 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 2 | 2004 | 2527 | 0.040 |
Why?
| | Leukocyte Common Antigens | 1 | 2020 | 88 | 0.040 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2004 | 449 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 824 | 0.040 |
Why?
| | Blood Gas Analysis | 1 | 2020 | 83 | 0.040 |
Why?
| | Cardiovascular Diseases | 1 | 2012 | 2168 | 0.040 |
Why?
| | Stromal Cells | 1 | 2020 | 124 | 0.040 |
Why?
| | Bicarbonates | 1 | 2020 | 45 | 0.040 |
Why?
| | Birds | 1 | 2020 | 92 | 0.040 |
Why?
| | Hematoma, Subdural | 1 | 2019 | 20 | 0.040 |
Why?
| | Software | 1 | 2025 | 690 | 0.040 |
Why?
| | DNA, Bacterial | 1 | 2021 | 342 | 0.040 |
Why?
| | Endpoint Determination | 1 | 2020 | 83 | 0.040 |
Why?
| | Skull Fractures | 1 | 2019 | 35 | 0.040 |
Why?
| | Phosphorylation | 1 | 2004 | 1732 | 0.040 |
Why?
| | Dopamine | 1 | 2022 | 283 | 0.040 |
Why?
| | Recurrence | 2 | 2012 | 1135 | 0.040 |
Why?
| | Injury Severity Score | 1 | 2021 | 600 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2022 | 784 | 0.040 |
Why?
| | Child Health | 1 | 2020 | 157 | 0.040 |
Why?
| | Radiation Exposure | 1 | 2019 | 63 | 0.040 |
Why?
| | Cardiac Output | 1 | 2019 | 179 | 0.040 |
Why?
| | Intracranial Hemorrhages | 1 | 2019 | 100 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2019 | 114 | 0.040 |
Why?
| | Interferon-alpha | 1 | 2020 | 197 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2024 | 846 | 0.040 |
Why?
| | Regression Analysis | 1 | 2021 | 1003 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 730 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 488 | 0.030 |
Why?
| | Complement Activation | 1 | 2021 | 411 | 0.030 |
Why?
| | American Heart Association | 1 | 2020 | 350 | 0.030 |
Why?
| | Staphylococcus aureus | 1 | 2022 | 455 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2019 | 304 | 0.030 |
Why?
| | Maternal Exposure | 2 | 2012 | 213 | 0.030 |
Why?
| | Developmental Disabilities | 1 | 2021 | 281 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2020 | 267 | 0.030 |
Why?
| | Data Collection | 1 | 2020 | 633 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2020 | 433 | 0.030 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 174 | 0.030 |
Why?
| | Rats | 2 | 2004 | 5597 | 0.030 |
Why?
| | Seasons | 1 | 2020 | 556 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2004 | 969 | 0.030 |
Why?
| | Creatinine | 1 | 2019 | 506 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2017 | 69 | 0.030 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 358 | 0.030 |
Why?
| | Mortality | 1 | 2020 | 375 | 0.030 |
Why?
| | Animals | 5 | 2020 | 38058 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2024 | 885 | 0.030 |
Why?
| | Homozygote | 1 | 2017 | 199 | 0.030 |
Why?
| | Middle Aged | 3 | 2024 | 35875 | 0.030 |
Why?
| | Causality | 1 | 2017 | 126 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2024 | 727 | 0.030 |
Why?
| | Calcium | 1 | 2022 | 1183 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1489 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1886 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2018 | 405 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2004 | 4154 | 0.030 |
Why?
| | Extracellular Matrix | 1 | 2020 | 553 | 0.030 |
Why?
| | Social Class | 1 | 2018 | 268 | 0.030 |
Why?
| | Point-of-Care Systems | 1 | 2018 | 187 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2017 | 402 | 0.030 |
Why?
| | Family | 1 | 2020 | 679 | 0.030 |
Why?
| | Glucocorticoids | 1 | 2020 | 535 | 0.030 |
Why?
| | Linear Models | 1 | 2018 | 854 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2016 | 140 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2020 | 717 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1658 | 0.030 |
Why?
| | Registries | 1 | 2023 | 2385 | 0.030 |
Why?
| | Body Weight | 1 | 2019 | 976 | 0.030 |
Why?
| | Communication | 1 | 2021 | 965 | 0.030 |
Why?
| | Proteins | 1 | 2000 | 1021 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2022 | 2832 | 0.030 |
Why?
| | Orthomyxoviridae | 1 | 2014 | 40 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2020 | 767 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1694 | 0.030 |
Why?
| | Child Health Services | 1 | 2016 | 185 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 2115 | 0.020 |
Why?
| | Protein Binding | 1 | 2019 | 2273 | 0.020 |
Why?
| | Immune System | 1 | 2013 | 179 | 0.020 |
Why?
| | Inflammation | 1 | 2023 | 2878 | 0.020 |
Why?
| | Databases, Factual | 1 | 2018 | 1486 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 2310 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1720 | 0.020 |
Why?
| | Vitamin D Deficiency | 1 | 2013 | 186 | 0.020 |
Why?
| | Depression | 1 | 2021 | 1558 | 0.020 |
Why?
| | Algorithms | 1 | 2019 | 1837 | 0.020 |
Why?
| | Models, Biological | 1 | 2019 | 1821 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2012 | 338 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2012 | 573 | 0.020 |
Why?
| | Electrocardiography | 1 | 2012 | 662 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2013 | 576 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 1173 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2847 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2012 | 869 | 0.010 |
Why?
| | Global Health | 1 | 2008 | 401 | 0.010 |
Why?
| | Mice | 1 | 2020 | 18339 | 0.010 |
Why?
| | Embryo, Mammalian | 1 | 2000 | 232 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2000 | 540 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3890 | 0.010 |
Why?
|
|
Mourani's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|